Lipoprotein removal by soluble enzymes

Details Lipoprotein removal by soluble enzymes Lipoprotein removal by soluble enzymes

A - Human Necessities

61

K

A61K 38/46 (2006.01) A61K 47/48 (2006.01)

Patent

CA 2049119

A therapeutically effective amount of soluble phospholipase A2 is administered into a subject for lowering the low density lipoproteins ("LDL") in the blood. Phospho- lipase A2 modifies the plasma LDL by hydrolyzing the phospholipids present in LDL. As a result, the modified LDL is rapidly removed from the bloodstream by the catabolic processes.

Une dose thérapeutique de la phospholipase soluble A2 est administrée à un sujet afin d'abaisser sa teneur sanguine en lipoprotéines de faible densité (« LDL »). La phospholipase A2 modifie la concentration plasmatique des LDL en hydrolysant les phospholipides qu'ils contiennent. Subséquemment, les LDL modifiés sont éliminés rapidement de la circulation sanguine par catabolisme.

Affiliated with

Also associated with

Rating

Lipoprotein removal by soluble enzymes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipoprotein removal by soluble enzymes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoprotein removal by soluble enzymes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1644155